Japan Nucleic Acid Therapeutics Cdmo Market Size & Outlook
Japan nucleic acid therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Japan nucleic acid therapeutics cdmo market highlights
- The Japan nucleic acid therapeutics cdmo market generated a revenue of USD 512.1 million in 2023 and is expected to reach USD 1,468.4 million by 2030.
- The Japan market is expected to grow at a CAGR of 16.2% from 2024 to 2030.
- In terms of segment, rna-based therapies was the largest revenue generating type in 2023.
- Gene Therapy is the most lucrative type segment registering the fastest growth during the forecast period.
Nucleic acid therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 512.1 million |
| Market revenue in 2030 | USD 1,468.4 million |
| Growth rate | 16.2% (CAGR from 2023 to 2030) |
| Largest segment | Rna-based therapies |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, RNA-based Therapies |
| Key market players worldwide | Catalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp |
Other key industry trends
- In terms of revenue, Japan accounted for 3.8% of the global nucleic acid therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China nucleic acid therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,993.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nucleic Acid Therapeutics CDMO Market Scope
Nucleic Acid Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan nucleic acid therapeutics cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nucleic acid therapeutics cdmo market will help companies and investors design strategic landscapes.
Rna-based therapies was the largest segment with a revenue share of 65.71% in 2023. Horizon Databook has segmented the Japan nucleic acid therapeutics cdmo market based on gene therapy, rna-based therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The nucleic acid therapeutics CDMO market in Japan is anticipated to grow at a CAGR of 16.3% due to various factors such as the growing pharmaceutical industry, increasing demand for outsourcing services, and rising R&D activities.
Moreover, gene & RNA therapy can be made effective by combining it with other types of treatments with the support of collaborative research and approval for products to treat various diseases.
For instance, in November 2023, Arcturus Therapeutics & CSL announced that Japan's Ministry of Health, Labour and Welfare approved ARCT-154.
Reasons to subscribe to Japan nucleic acid therapeutics cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan nucleic acid therapeutics cdmo market databook
-
Our clientele includes a mix of nucleic acid therapeutics cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan nucleic acid therapeutics cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Japan nucleic acid therapeutics cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan nucleic acid therapeutics cdmo market size, by type, 2018-2030 (US$M)
Japan Nucleic Acid Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
